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Pharmacogenetic-Pharmacokinetic Interactions 
in Drug Marketing Authorization Applications 
via the European Medicines Agency Between 
2014 and 2017
Marc Maliepaard1,2,* , Timi Toiviainen1,3 , Marie L. De Bruin3,4  and Didier Meulendijks1
This study aimed to determine to which extent data on potential pharmacogenetic-pharmacokinetic (PG-PK) 
interactions are provided to, and assessed by, the European Medicines Agency (EMA) in novel drug marketing 
authorization applications (MAAs), and whether regulatory assessment of PG-PK interactions is adequate or could be 
optimized. For this purpose, we retrospectively analyzed MAAs of small molecule drugs assessed by the EMA between 
January 2014 and December 2017. As per two key requirements in the EMA’s guideline, we analyzed cases where (i) 
a single functionally polymorphic drug metabolizing enzyme (DME) metabolizes > 25% of the drug, or (ii) the drug’s 
PK shows high interindividual variability not explained by other factors than PG. Results showed that, of 113 drugs 
analyzed, 53 (47%) had ≥ 1 functionally polymorphic DME accounting for > 25% of the drug’s metabolism, yielding 55 
gene-drug pairs. For 36 of 53 (68%) of the products, CYP3A4 was the major DME. Compliance with European Union 
(EU) guidance on PG-PK issues in drug development was notably different for CYP3A4 substrates vs. non-CYP3A4 
substrates. Adequate PG-PK data were provided during registration in 89% (16/18) of cases concerning non-CYP3A4 
substrates, compared with 32% (12/37) of cases concerning CYP3A4 substrates. Concluding, PG-PK interactions 
related to non-CYP3A4 substrate drugs were, in general, addressed adequately in EU MAAs. PG-PK information on 
CYP3A4 substrates was available less frequently, despite some available evidence on the functional relevance of 
CYP3A4 polymorphisms. A more harmonized approach toward assessment of PG-PK issues in EU MAAs seems 
warranted, and a discussion on the relevance of CYP3A4 polymorphisms, such as CYP3A4*22, is recommended.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Guidelines from the European Medicines Agency (EMA) 
are available for assessing pharmacogenetic-pharmacokinetic 
(PG-PK) interactions in marketing authorization applications 
of novel drugs.
WHAT QUESTIONS DID THIS STUDY ANSWER?
 This study investigated to what extent potential (PG-PK) 
interactions with novel drugs are included in drug development 
plans, and are assessed by regulators in accordance with current 
EMA guidelines on PG-PK interactions.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 This study shows that PG-related gene–drug interactions 
were, in general, addressed as required per the EMA’s PG-PK 
guideline, when it concerned non-CYP3A4 substrate drugs. 
Adequate PG-PK data were available at approval for 16 of 18 of 
drugs (89%). However, when it concerned CYP3A4 substrates, 
PG-PK information was available at the time of registration in 
only a minority of cases (i.e., for 12/37 (32%) of the novel drugs). 
Lack of recognition of CYP3A4 as a functionally polymorphic 
enzyme with potential clinical relevance, and, in particular, the 
relevance of poor metabolizer genotypes, such as CYP3A4*22, 
is the likely cause for this finding.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 CYP3A4 genotypes have in recent years been shown to have 
a clinically relevant impact on the PK of some drugs that are 
CYP3A4 substrates. The findings from this study warrant in-
creased awareness towards the potential for PG-PK interactions 
with drugs that are CYP3A4 substrates during drug develop-
ment and during assessment of MAAs for novel drugs in the EU.
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There is large variability in how patients respond to medicines, 
and the efficacy and safety of drugs vary widely for virtually all 
drugs. Patient characteristics that affect drug pharmacokinetics 
(PK) and/or pharmacodynamics (PD) contribute to this variabil-
ity, including factors such as age, weight, sex, renal function, and 
hepatic function. Over the past decades, it has become clear that 
also genetics (i.e., DNA characteristics) can have a key influence 
on drugs’ PK/PD and consequently on efficacy and safety.1
Pharmacogenetics (PG) is the study of associations between pa-
tients’ genetics and drug response. The association between genetic 
polymorphisms in drug metabolizing enzymes (DMEs) and drug 
PK/PD has been studied extensively, and functionally polymor-
phic DMEs are often referenced in drug labeling.2,3 Cytochrome 
P450 enzymes are the most well-known examples of functionally 
polymorphic DMEs. In case of a functionally polymorphic DME, 
based on the degree of activity of DMEs as determined by pheno-
typing or predicted by genotype, patients are typically classified as: 
extensive metabolizer (normal metabolic activity), ultrarapid me-
tabolizer (above-average activity), intermediate metabolizer (be-
low-average activity), or poor metabolizer (PM; strongly reduced 
activity). Clinically relevant impact of DME phenotype has been 
demonstrated for many drugs, including tricyclic antidepressants, 
opioids, and cardiovascular medications.1
In general, an enzyme is considered polymorphic when the most 
common (“wild-type”) allele has a frequency of ≤  99% (i.e., at 
least 1% of the subjects has a polymorphic gene sequence).4 For 
a number of DMEs (e.g., CYP2D6, CYP2C9, CYP2C19, and 
CYP3A4), polymorphic genotypes represent up to 40%, 28%, 
30%, and 8%, respectively, of the total population.5,6 Analogous to 
inhibition of a DME by concomitantly administered drugs, which 
may lead to clinically relevant increases in blood concentrations of 
the drug, gene–drug interactions have the potential to cause clini-
cally relevant effects on drug safety and efficacy in clinical practice.
A key example of a relevant gene–drug interaction is the inter-
action between CYP2C19 genotype and clopidogrel efficacy in 
patients with acute coronary syndrome.7 Because clopidogrel is a 
prodrug that needs to be activated in vivo by CYP2C19, reduced 
CYP2C19 activity can lead to reduced pharmacological effect. 
Although individual studies on clopidogrel and CYP2C19 did 
not always show consistent outcomes, a large meta-analysis in-
dicated that clopidogrel-treated patients with acute coronary 
syndrome undergoing percutaneous coronary intervention who 
are CYP2C19*2 heterozygotes or homozygotes (combined fre-
quency ~ 28% in white patients) have an increased risk for major 
adverse cardiovascular events as compared with CYP2C19*1 ho-
mozygotes and increased risks of stent thrombosis.8 The grow-
ing body of literature implicating CYP2C19*2 (and probably 
other loss-of-function alleles) in adverse clopidogrel responses 
has prompted the US Food and Drug Administration (FDA) 
to implement a “black box warning” on the increased risk for 
major adverse cardiovascular events, and, in the European Union 
(EU) clopidogrel Summary of Product Characteristics (SmPC), 
a warning is included regarding lower formation of active me-
tabolites of clopidogrel and a smaller effect on platelet function 
in patients who are poor CYP2C19 metabolizers.9,10 Examples 
of other drugs for which PG-PK interactions are considered 
important are eliglustat, approved by the FDA and the European 
Medicines Agency (EMA) in 2014/2015 for the treatment of 
Gaucher disease type 1 specifically in patients who are poor, in-
termediate, or extensive CYP2D6 metabolizers,11,12 and sipon-
imod, a multiple sclerosis drug being metabolized by CYP2C9, 
for which the FDA and the EMA approved recommended dos-
age is determined by CYP2C9 genotype.13,14 These examples 
show that availability of PG-PK data and assessment of these 
data by regulators can be critical to avoid safety and efficacy is-
sues and can serve as a tool to tailor drug treatment to the right 
patients at the right dose.
Besides relatively common polymorphisms, the cumulative fre-
quency of rare variants, which lead to PM phenotypes may also be 
relevant, such as for CYP3A4 and to a lesser extend CYP2C9, and 
these rare variants may ultimately contribute substantially to met-
abolic variability in the patient population.15 However, because at 
this stage no regulatory requirements are posed on such rare vari-
ants, this will not be included in this paper.
Of note, although metabolic activity of the most prominently 
involved CYP DME, CYP3A4, is known to be highly variable 
between subjects, the CYP3A4 gene was until recently con-
sidered not to have functionally relevant polymorphisms.16,17 
However, in 2011 Wang et al. identified the CYP3A4*22 allele, 
a polymorphism that has since been associated with PG-PK in-
teractions (e.g., lower clearance of tacrolimus; 30% lower dose 
requirements) and cyclosporin A (53% higher concentration) 
in renal transplant patients, and 2.5-fold higher serum concen-
trations of quetiapine.6,18 CYP3A4*22 has also been reported 
to substantially influence the PK of statins1,6,19 and different 
drugs used in oncology, including sunitinib, pazopanib, and 
docetaxel.20–22 For other drugs, there are contradictory reports 
on the effect of CYP3A4*22 on PK (e.g., for voriconazole,23,24 
and clopidogrel).25 Overall, however, the available evidence 
seems sufficient to indicate that CYP3A4 polymorphisms, and 
specifically CYP3A4*22, should be considered during develop-
ment of novel drugs, which are substrate for CYP3A4.
In view of the importance of having data regarding PGs 
and potential PG-PK interactions available prior to marketing 
authorization/drug approval, the EMA released in 2012 the 
“Guideline on the use of pharmacogenetic methodologies in the 
pharmacokinetic evaluation of medicinal products” (hereafter: the 
EMA PG-PK guideline).26 This guideline provides a framework 
for using PG data during drug development. The FDA and the 
Pharmaceuticals and Medical Devices Agency (PMDA) in the 
United States and Japan, respectively, have published similar 
guidance.27
The EMA PG-PK guideline describes two key criteria to pro-
vide guidance on when PG-PK should be studied in confirmatory 
studies: (i) if there is a single PK enzyme that metabolizes > 25% 
of the drug in vivo based on early clinical studies and is known to 
be polymorphic, and (ii) when the drug’s PK shows large interin-
dividual variability that cannot be explained by other intrinsic or 
extrinsic factors.
In the EMA PG-PK guideline, a cutoff of 25% is defined, above 
which the clinical relevance of a genetic polymorphism should 
be investigated during the drug development phase.26 This 25% 
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cutoff is in line with the cutoff that is applied by the EMA in case 
of drug–drug interactions (see EMA Guideline on the investiga-
tion of drug interactions).28 This cutoff seems reasonable, because, 
for a PM, the effect of the genetic polymorphism on exposure of 
a drug may be comparable with the effect of a strong inhibitor of 
the enzyme involved. The term “high interindividual variability” 
is not further specified in the EMA guideline, although, in the 
EMA Guideline on Investigation of Bioequivalence, a cutoff for 
high PK variability of 30% is described.29
To which extent availability of PG data in the initially submit-
ted dossier for the marketing authorization application (MAA) 
and regulatory assessment of the MAA is in line with current 
guidelines has not been systematically studied previously. In this 
study, we analyzed all MAAs that were submitted to the EMA via 
the Centralized Procedure between January 2014 and December 
2017, in order to determine how PG was implemented in the drug 
development plan, how these PG data subsequently was assessed, 
and whether the assessment of PG-PK issues is currently adequate 
or could be optimized.
METHODS
Study design and objectives
We performed a retrospective analysis of novel drugs that were assessed 
by the EMA between January 2014 and December 2017. In part 1 and 
2 of the analysis, we investigated to which extent the above-mentioned 
requirements of the EMA guideline (1 and 2, respectively) were followed. 
In both parts of the study, the objective was to determine the extent of 
availability of PG-PK data in the initially submitted dossier for the MAA 
as well as how the data were assessed by the EMA. The results of these 
analyses were used to determine whether assessment of PG-PK issues in 
EU MAAs is currently adequate or could be optimized. The availability 
of PG-PK data in MAAs over time within the 2014–2017 study period 
was also assessed.
Data collection
All medicinal products for human use, which were assessed via the 
Centralized Procedure by the EMA and were either granted or refused 
marketing authorization between January 2014 and December 2017 
(n  =  320; Figure 1), were identified and retrieved via the EMA data-
base (https://www.ema.europa.eu). Only products with a full dossier, 
for a novel medicinal product were included. Applications building on 
previously authorized medicines (e.g., generics (n = 41) and biosimilars 
(n = 24)), were excluded, because, for these products in general, no new 
PG-PK data are submitted. Finally, biologicals (n  =  78) were excluded 
from the analysis, becaused such pharmaceuticals are metabolized by 
pathways for which the effect of PGs is not well-established (e.g., pro-
teolytic pathways). This selection yielded 113 small molecule products, 
which were included in the analysis.
Data on the drug’s metabolic pathways, the DMEs involved, and 
the drug’s general PK, including interindividual variability in PK, 
were extracted from publicly available data sources (i.e., the EMA 
European Public Assessment Report (EPAR), the SmPC, the EMA 
website, as well as from internal data sources at the Dutch Medicines 
Evaluation Board (MEB) including assessment reports of the EU 
Rapporteur and Co-Rapporteurs). In addition, for each drug, the sci-
entific literature was searched using PubMed and prespecified search 
strings to collect information on PG-PK interactions (details pro-
vided in Table S1).
If a single enzyme’s contribution to the drug’s metabolism was > 25% 
in vivo (i.e., in human subjects or patients), the respective DME was con-
sidered to be a “major DME” for the purpose of this study (i.e., an enzyme 
with a major contribution to the drug’s PK).
Information on the relevance of genetic polymorphisms
The importance of genetic polymorphisms for the identified major 
DMEs was determined based on the available scientific literature. If 
the polymorphism was known to cause interindividual differences 
in exposure of drugs metabolized by the respective DME and it was 
determined that this could potentially inf luence the drug’s efficacy 
and/or safety (as determined by consensus between three of the in-
vestigators: M.M., T.T., and D.M.), and, in addition, the frequency of 
the functional polymorphism was known to be >  1% in white pop-
ulations,26 the enzyme was determined to be a “known functionally 
polymorphic DME.”
Products for which the major DME was known to be functionally 
polymorphic (hereafter “major functionally polymorphic DME”) were 
included in the primary analysis (Analysis 1). The remaining products 
for which no major functionally polymorphic DME was identified were 
included in the secondary analysis (Analysis 2) only in case the drug’s PK 
showed high interindividual variability (> 30% as indicated in the intro-
duction) that could not be explained by other intrinsic or extrinsic factors, 
like age, weight, sex, and renal or hepatic function. This is generally tested 
via a population PK model combining PK data from all clinical studies in 
the MAA dossier.
Data analysis
Analysis 1, involving drugs with a known major functionally polymor-
phic DME, was conducted in sequential steps. First, it was determined 
whether or not a major functionally polymorphic DME was acknowl-
edged by the applicant and/or the assessors/EMA Committee for 
Medicinal Products for Human Use (CHMP), subsequently whether 
or not PG-PK data were provided by the applicant, whether and at 
which stage additional PG-PK data were requested by the CHMP, and 
whether and how PG-PK data were provided as a result of the CHMP’s 
questions. The data were summarized and analyzed using descriptive 
statistics.
Analysis 2, involving drugs without a known major functionally 
polymorphic DME but with identified highly variable PK, followed 
a similar approach but focused on how frequently the CHMP raised 
questions about the potential impact/relevance of interindividual vari-
ability in PK not explained by other factors as mentioned above, how 
often these questions were asked specifically in relation to PG-PK, and 
whether or not the applicant provided PG-PK data as a result of the 
questions raised.
Figure 1 Flowchart describing selection of marketing authorization applications for inclusion in Analysis 1 and Analysis 2. Products with 
a known functionally polymorphic major DME were included in Analysis 1 and products with an indication for involvement of a functionally 
polymorphic DME based on high interindividual PK variability were included in Analysis 2. Products with no indication for functionally 
polymorphic DMEs based on PK variability and that did not have a known major functionally polymorphic DME involved in their metabolism, 
were excluded from further analyses. The pie chart represents the proportion of products having (blue) or not having (green) a known 
functionally polymorphic DME, or display high PK variability (red). The major functionally polymorphic DMEs included CYP1A2, CYP2C8, 
CYP2C9, CYP2C19, CYP2D6, CYP3A4, CES1, SULT1A1, UGT1A1, and UGT1A9. The nine major DMEs that were considered not to have 
relevant functionally polymorphisms were cathepsin A, UGT1A6, aromatic L-amino acid decarboxylase, aldehyde oxidase, and microsomal 
epoxide hydrolase. DME, drug metabolizing enzyme; EC, European Commission; EMA, European Medicines agency; PK, pharmacokinetics: high 
interindividual variability means > 30%.
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Procedures included in 
the study
(n=113) 
Major DME present in 
PK pathway 
(n=62)
No major DME present in PK 
pathway 
(n=51)
No major DME present in PK 
pathway or major DME is 
not a known functionally 
polymorphic enzyme 
(n=60)
High interindividual PK 
variability (suggestive of 








Major DME is a 





Human medicines in 
EMA database 
approved  in 2014-
2017 (n=320) Excluded (n=207):
• Generics (n=41) 
• Biosimilars (n=24)





Major DME is not a 
known functionally  
polymorphic enzyme 
(n=9) 
Major DME is a known functionally 
polymorphic enzyme
High interindividual PK variability 
(suggestive of potential PG-PK issue)
No high interindividual PK variability
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Last, to determine how the PG-PK data were ultimately reflected in the 
product SmPC, the SmPCs of the products included in both analyses were 
analyzed and the SmPCs PG-PK data summarized.
RESULTS
For 62 of 113 (55%) of the included products, a major DME was 
involved in the drug’s metabolism (Figure 1). Of these 62 prod-
ucts, there were 9 products with major DMEs, which were con-
sidered not to have known genetic polymorphisms of clinical 
relevance based on current scientific knowledge (i.e., cathepsin A 
and UGT1A6, aromatic L-amino acid decarboxylase, aldehyde 
oxidase, and microsomal epoxide hydrolase). After exclusion of 
these 9 products, 53 products (47% of 113) remained, which were 
identified as having a major functionally polymorphic DME. 
Two products had two potential gene–drug interactions, yielding 
55 gene-drug pairs. These products were included in Analysis 1. 
The functionally polymorphic DMEs involved were CYP1A2, 
CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CES1, 
SULT1A1, UGT1A1, and UGT1A9.
From the 60 of 113 products for which no major functionally 
polymorphic DME was identified, 17 products (15% of 113) 
were identified as having high interindividual PK variability (i.e., 
a potential indication for PG-PK effects), and were included in 
Analysis 2. A total of 43 products (38% of 113) did not have high 
PK variability and did not have a major functionally polymorphic 
DME involved in their metabolism, and these products were, 
therefore, excluded from further analysis (Figure 1).
Table 1 presents an overview of products and characteristics for 
all the products included in Analysis 1 and Analysis 2.
Analysis of drugs metabolized by a known major functionally 
polymorphic DME (Analysis 1)
For 37 of 53 (70%) of the products that were included in Analysis 
1, CYP3A4, CYP3A5, or CYP3A4/5 (32, 1, and 4 products, re-
spectively) was identified as the major functionally polymorphic 
DME (Figure 2). Because of the highly similar substrate selectiv-
ity between these DME isoforms, these enzymes are often referred 
to as one group, CYP3A4/5.30 The next most prominent DMEs 
were UGT1A1, CYP2D6, and CES1 (3 products (6%) each). 
The remainder of the DMEs occurred for only one or two prod-
ucts each. Two of the products had two major functionally poly-
morphic DMEs (i.e., CYP2C8 and CES1; and CYP2D6 with 
CYP3A4) and, therefore, among 53 drugs, 55 gene-drug pairs 
were identified.
Of the 53 drugs in Analysis 1, the applicant provided PG-PK 
data considering the relevant functionally polymorphic DME in 
the initially submitted dossier for the MAA in 9 of 53 (17%) of ap-
plications (Figure 3). In the remaining 44 of 53 procedures (83%), 
PG-PK data were not provided by the applicant in the initially sub-
mitted dossier. Within these procedures, in 9 of 44 (20%) of these 
cases in which there was a major functionally polymorphic DME 
involved in the drug’s PK (in light of currently available scientific 
knowledge and in the context of this study), this was not recog-
nized nor questioned by the EMA during assessment of the appli-
cation. In all nine of these cases, the polymorphic DME involved 
was CYP3A4. The presence of a major functionally polymorphic 
DME was acknowledged and/or questioned by the regulatory 
authorities during assessment of the application in the remaining 
35 of 44 (80%) procedures. However, in only 18 of these 35 cases 
(51%), additional PG-PK data were requested. In 8 of these 18 
cases, the question concerned the potential relevance of CYP3A4 
polymorphisms.
As shown in Figure 3, in 4 of 35 of the cases (11%) in which 
a major functionally polymorphic DME was identified by the 
CHMP, no PG-PK data were requested, and no statement on 
the expected relevance of the polymorphism was provided by the 
EMA. Further, in 13 of 35 cases (37%), it was a priori concluded 
by CHMP that such polymorphisms were not expected to be 
clinically relevant. The latter two situations combined, in which 
no further data were requested, add up to 17 of 35 (49%) of 
the cases in which a major functionally polymorphic DME was 
identified by the CHMP. In 16 of these 17 cases, the potentially 
relevant DME involved was CYP3A4, another one concerned 
CYP2C8.
In all of the 18 cases where questions were raised by the CHMP, 
PG-PK data were subsequently submitted by the applicant, either 
in the form of published data or in-house data, and, in all these 
cases, the questions were considered answered adequately by the 
applicants according to the Rapporteurs/CHMP. In 4 of 18 cases 
(22%), the applicant provided a PG-PK study on the major DME 
as a postauthorization measure and in 13 cases (n = 13/18; 72%) 
the applicant referred to the scientific literature or the dossier 
in their answers without conducting further studies or analyses. 
There was one case (1/18; 6%) where the applicant provided a 
new PG study before the marketing authorization as a result of 
the question raised during assessment of the dossier.
Overall, PG-PK data had been provided at the end of the assess-
ment procedure in 27 (9 + 18; green boxes in Figure 3) of 53 pro-
cedures (51%), and were not submitted/available in the remaining 
26 procedures (49%; 9 + 4 + 13; red boxes in Figure 3).
Figure 4 illustrates the relationship between the type of enzyme 
involved in procedures in which a major functionally polymorphic 
DME was identified (included in Analysis 1) and whether or not 
data to address the issue of potential PG-PK issues were provided 
during the procedure. This figure illustrates that for all DMEs 
combined excluding CYP3A4/5, PG-PK data were provided 
during the assessment of the procedure in 16 of 18 cases (89%). In 
cases where CYP3A4/5 was involved, on the other hand, in only 
12 of 37 cases (32%) PG-PK data were provided.
Since the regulatory guideline on PG-PK was issued in 2012, 
the proportion of applications where PG-PK data were requested 
was analyzed by year of drug approval. No clear pattern over the 
years analyzed was noted, with PG-PK data concerning major 
functionally polymorphic DMEs provided in 53% of the proce-
dures in 2014 (n = 9/17), 56% in 2015 (n = 9/16), 60% in 2016 
(n = 6/10), and 30% in 2017 (n = 3/10).
Analysis of drugs with high interindividual variability in PK 
(Analysis 2)
In line with the PG-PK guideline, for drugs that showed high 
interindividual variability in area under the curve (AUC) which 
could not be explained by known factors other than PG, questions 
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Table 1 Overview and characteristics of small molecule products included in Analysis 1 and Analysis 2
Product characteristics
Major DME is a known functionally  
polymorphic enzyme Large interindividual PK variability
n = 53 (%) n = 17 (%)
Authorization status
Authorized 47 88.7 17 100
Authorized and later withdrawn 1 1.9 0 0
Refused 5 9.4 0 0
Year of commission decision
Granted marketing authorization
2017 8 15.1 4 23.5
2016 10 18.9 2 11.8
2015 16 30.2 4 23.5
2014 14 26.4 7 41.2
Refused marketing authorization
2017 2 3.8 0 0.0
2016 0 0.0 0 0.0
2015 0 0.0 0 0.0
2014 3 5.7 0 0.0
Procedure started
2017 1 1.9 1 5.9
2016 8 15.1 2 11.8
2015 8 15.1 3 17.6
2014 15 28.3 3 17.6
2013 15 28.3 6 35.3
2012 6 11.3 2 11.8
Type of authorization
Conditional approvala 3 5.7 1 5.9
Exceptional circumstances 0 0.0 0 0.0
Normal 50 94.3 16 94.1
Orphan status
Yes 16 30.2 3 17.6
No 37 69.8 14 82.4
New active substanceb
Yes 48 90.6 15 88.2
No 5 9.4 2 11.8
ATC codingc
A-Alimentary tract and metabolism 5 9.4 3 17.6
B-Blood and blood forming organs 2 3.8 0 0.0
C-Cardiovascular system 4 7.5 1 5.9
D-Dermatologicals 0 0.0 0 0.0
G-Genito-urinary system and sex hormones 1 1.9 0 0.0
H-Systemic hormonal preparations, excluding sex 
hormones and insulins
0 0.0 0 0.0
J-Anti-infectives for systemic use 8 15.1 6 35.3
L-Antineoplastic and immunomodulating agents 19 35.8 4 23.5
M-Musculoskeletal system 1 1.9 0 0.0
N-Nervous system 8 15.1 2 11.8
 (Continued)
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about interindividual variability were asked in 16 of 17 procedures 
(94%). In eight procedures (50%), these questions focused on in-
terindividual variability without specifying potential causes. In 
one procedure (6%), the question was specifically related to PG-
PK, and in seven additional cases (44%), there were separate ques-
tions about both PG-PK and interindividual PK variability. In 8 
of 16 cases (50%), the applicant provided a discussion on (pub-
lished or in-house) PG-PK data as a result of the question. None of 
the products included in Analysis 2 were ultimately considered by 
the CHMP to possess clinically relevant PG-PK interactions, as 
evident from the currently included information in the SmPC for 
the products involved.
PG-PK information in product labeling/SmPC
Of the 53 products that had a major functionally polymorphic 
DME involved in the drug’s metabolism and of which 47 are cur-
rently on the market, 12 products (26%) have information regard-
ing PGs of the respective DME in the SmPC. For nine of these 
products that are mentioned in the SmPC, the potential impor-
tance of PG-PK was recognized by the applicant in the initially 
submitted dossier for the MAA, for three products information 
on PG-PK was requested by CHMP during the assessment proce-
dure. Table 2 illustrates in which sections the information on PK-
related PGs was included. For six products, the SmPC contains 
statements describing that the PG-PK interactions are considered 
Product characteristics
Major DME is a known functionally  
polymorphic enzyme Large interindividual PK variability
n = 53 (%) n = 17 (%)
P-Antiparasitic products, insecticides, and 
repellents
0 0.0 0 0.0
R-Respiratory system 2 3.8 0 0.0
S-Sensory organs 0 0.0 0 0.0
V-Various 1 1.9 0 0.0
No coding 2 3.8 1 5.9
Route of administration
Oral 49 92.5 15 88.2
Inhalation 2 3.8 1 5.9
s.c./i.v. 2 3.8 1 5.9
ATC, Anatomical Therapeutic Chemical Classification System; DME, drug metabolizing enzyme; PK, pharmacokinetic.
aConditional approval current status was based on data provided at the European Medicines Agency (EMA) website in February 2018. bNew active substance 
status as concluded by the EMA during registration procedure. cATC coding was based on the ATC/DDD Index 2018 (https://www.whocc.no/atc_ddd_index /).
Table 1 (Continued)
Figure 2 Frequency of the major functionally polymorphic DMEs included in the Analysis 1. The inner circle represents the frequency of 
individual DMEs, the outer purple circle represents the total frequency of CYP3A4 and CYP3A5. The total number of DMEs exceed the number 
of products (53 = 100%; n = 55), because two of the products had two major gene–drug interactions, so two major functionally polymorphic 
DMEs involved in their metabolism. DME, drug metabolizing enzyme.
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Figure 3 Flowchart describing interaction between the applicant and the regulatory authorities in case a major functionally polymorphic 
DME was present (Analysis 1). In total, PG-PK data were provided in 9 + 18 = 27 of 53 procedures (51%; indicated in green boxes) and were 
not submitted in 9 + 4 + 13 = 26 of 53 procedures (49%; indicated in red boxes). The clinical relevance of the gene–drug interactions was 
decided upon by EMA Committee for Medicinal Products for Human Use during assessment of the MAA, generally based on the magnitude 
of (expected) effect on exposure by functionally polymorphic DME genotypes in the context of the therapeutic window of the drug. N.B. 
% values in the fourth row do not add up to 100% due to rounding issues. DME, drug metabolizing enzyme; PG-PK, pharmacogenetic-
pharmacokinetic.
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clinically relevant, including those resulting in different dosing 
recommendations or increased risk of adverse drug reactions for 
genetic subpopulations. Of these six products, four were already 
recognized in the initially submitted dossier for the MAA, and 
two were recognized by the CHMP during assessment. The clin-
ical relevance of the gene–drug interactions, as described in the 
SmPC, was decided upon by the CHMP during assessment of 
the MAA, generally based on the magnitude of (expected) effect 
on exposure by functionally polymorphic DME genotypes in the 
context of the therapeutic window of the drug. In case functional 
polymorphisms of the DME were not considered to be clinically 
relevant, only descriptive data were provided in section 5.2 of 
the SmPC. Table 3 shows that PG-PK data were included in the 
SmPC only if the PG-PK data were provided/discussed during the 
procedure.
DISCUSSION
The purpose of this study was to evaluate how PK-related gene–
drug interactions were implemented in the drug development 
plan, how this was assessed for novel drugs authorized in the 
European Union by the EMA, and whether or not regulatory as-
sessment of potential PG-PK interactions is currently adequate or 
could be optimized.
We found that for medicinal products registered in the 
European Union between 2014 and 2017, in only 51% (27/53) 
of the procedures where a functionally polymorphic DME played 
a major role in the drug’s metabolism, PG-PK information was 
ultimately included in the registration dossier at the time of reg-
istration. Further, although in 80% (35/44) of the procedures 
where no PG-PK data were provided upfront by the applicant, 
a potential PG-PK issue for the novel drug was acknowledged 
during assessment by CHMP, additional PG-PK data were only 
requested by CHMP in 51% (18/35) of these cases. Last, in 
~  20% (9/44) of the procedures involving a functionally poly-
morphic DME with potential clinical relevance according to our 
analysis, but where no PG-PK data were provided by the appli-
cant, the potential PG-PK issue was not acknowledged at all by 
the applicant nor regulators. We noted no trend toward increase 
in the availability of PG-PK data for novel drugs over time, ac-
knowledging, however, the relatively short time period analyzed. 
Further, although the PG-PK guideline states that a gene–drug 
interaction may be mimicked by a drug-interaction study in order 
to predict consequences of specific genetic polymorphism in pa-
tients, we did not encounter such data in the dossiers that were 
included in this study.
These findings may suggest that either the PG-PK guideline, is-
sued in 2012, is not always followed by applicants and regulators, 
or, perhaps more likely, that there are varying interpretations on 
which are relevant functionally polymorphic DMEs. In this re-
spect, it is important to note the role that CYP3A4 had on the 
outcome of our analysis. As indicated in the introduction, the cur-
rently available evidence suggests that a potentially relevant effect 
of CYP3A4 genotypes, in particular CYP3A4*22, on the PK of 
drugs, which are CYP3A4 substrate cannot be excluded a priori, 
which is why we considered CYP3A4 as a functionally polymor-
phic DME in this analysis. Lower compliance with the PG-PK 
guideline was mainly seen in regard to CYP3A4 substrates, most 
likely as a result of the fact that CYP3A4*22 was not consistently 
acknowledged by industry and assessors of regulatory authorities 
as potentially clinically relevant. Therefore, a separate discussion 
for products where CYP3A4 is the major DME and products for 
which it is not is warranted.
In our study, we observed that for 25 (i.e., all except one) 
of the 26 of 35 procedures where the polymorphic DME was 
not acknowledged in the assessment, no PG-PK data were re-
quested by regulators, or polymorphisms were not expected to 
Figure 4 Relationship between type of functionally polymorphic DME and whether or not data regarding the potential PG-PK interaction were 
provided during the assessment procedure. Applications in which PG-PK data on an identified functionally polymorphic DME were provided are 
indicated in green, vs. cases in which no data were provided shown in orange. The total number is 55 (gene-drug pairs), in the context of 53 
procedures/drugs. DME, drug metabolizing enzyme; PG-PK, pharmacogenetic-pharmacokinetic.
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have clinically relevant effects (red boxes in Figure 3), this con-
cerned CYP3A4/5. As shown in Figure 4, this led to the situa-
tion that only in 12 of 37 cases (32%) in which CYP3A4/5 was 
involved, PG-PK data were ultimately provided. Conversely, for 
non-CYP3A4/5 substrate drugs, PG-PK data were provided in 
the vast majority of cases (16/18; 89%). These findings suggest 
that the EMA PG-PK guideline is well appreciated by applicants 
and assessors, but that the relatively large number of products for 
which no PG-PK data were submitted during the assessment was 
mostly due to different interpretations or awareness regarding the 
relevance of the CYP3A4 polymorphisms, such as CYP3A4*22.
Besides varying interpretations toward the relevance of CYP3A4 
polymorphisms, the fact that the drug development processes gen-
erally takes 10  years or longer31,32 may have contributed to the 
finding that data on more recently identified clinically relevant 
polymorphisms, such as CYP3A4*22, were not generated at the 
time of the early-phase clinical studies and, hence, were not avail-
able at the time of MAA.
The results from this analysis illustrate the role that applicants 
and regulatory agencies jointly have in the safe and effective use of 
medicinal products. In a majority of the cases where a major func-
tionally polymorphic DME was involved but the initially submit-
ted dossier for the MAA did not contain data on potential PG-PK 
interactions, only after questions from the regulatory authorities’ 
data were provided/discussed. Further, it was noted that for two of 
the drugs in our dataset for which PG-PK data were only provided 
upon request by the CHMP, the outcome was ultimately consid-
ered clinically relevant, and information was included in the SmPC.
The fact that CYP3A4 was not consistently acknowledged as 
a potentially important functionally polymorphic DME during 
MAA assessment suggests there is room for improved harmoni-
zation in the European Union regarding which functionally poly-
morphic DMEs should be considered as “known functionally 
polymorphic enzymes,” with potential clinically relevant impact. We 
recommend that a list of acknowledged functionally polymorphic 
DMEs with potential clinical relevance be published by the regu-
latory agencies (e.g., as an appendix to the PG-PK guideline, which 
was developed by the EMA’s Pharmacogenomics Working Party).26 
By doing so, both applicants and regulatory assessors can agree on 
which are the functionally polymorphic DMEs that should be con-
sidered as potentially clinically relevant during drug development 
and assessment of MAAs, and for which genes potential PG-PK 
interactions should be investigated during drug development.
CONCLUSIONS
This study shows that PK-related gene–drug interactions are ad-
dressed adequately in EU Centralized Procedures, as required per 
the EMA’s PG-PK guideline, when it concerns non-CYP3A4 sub-
strate drugs. However, where CYP3A4 substrates are concerned, 
assessment of PG-PK data was found to be noncompliant with cur-
rent guidance in a majority of cases. This is likely the result of lack 
of recognition of CYP3A4 as a functionally polymorphic enzyme, 
and the fact that CYP3A4 genotypes, such as CYP3A4*22, do have 
the potential to lead to clinically relevant gene–drug interactions.
A more harmonized approach toward assessment of PG-PK is-
sues in the context of MAAs in the European Union is warranted 
in order to further improve the benefit/risk balance of drugs in ge-
netic subpopulations, and a discussion on the relevance of CYP3A4 
polymorphisms is recommended.
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Table 3 Distribution of PG-PK data in the SmPC in case PG-PK was studied or not
 
PG-PK data concerning major DMEs were 
provided (n = 27)
PG-PK data concerning major DMEs were 
not provided (n = 26) Total (n = 53)
No PG-PK data in 
SmPC
15 (55%) 26 (100%) 41 (78%)
PG-PK data in 
SmPC – not clinically 
relevant
6 (22%) 0 (0%) 6 (11%)
PG-PK data in SmPC 
– clinically relevant
6 (22%) 0 (0%) 6 (11%)
DME, drug metabolizing enzyme; PG-PK, pharmacogenetic-pharmacokinetic; SmPC, Summary of Product Characteristics.
The clinical relevance of the gene–drug interactions was decided upon by EMA Committee for Medicinal Products for Human Use during assessment of the 
marketing authorization application, generally based on the magnitude of (expected) effect on exposure by functionally polymorphic DME genotypes in the context 
of the therapeutic window of the drug.
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